1 INDICATIONS AND USAGE

Seasonal Allergic Rhinitis
Telfast oral suspension is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children 3 to 11 years of age.

2 DOSAGE AND ADMINISTRATION

Seasonal Allergic Rhinitis

Children 3 to 11 Years: The recommended dose of TELFAST oral suspension is 30 mg twice daily. A dose of 30 mg (5 mL) once daily is recommended as the starting dose in pediatric patients with decreased renal function [see Clinical Pharmacology (12.3)]. Shake bottle well, before each use.

3 DOSAGE FORMS AND STRENGTHS

TELFAST oral suspension is available as 30 mg/5 mL (6 mg/mL).

4 CONTRAINDICATIONS

TELFAST oral suspension are contraindicated in patients with known hypersensitivity to fexofenadine and any of the ingredients of TELFAST. Rare cases of hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnea, flushing and systemic anaphylaxis have been reported.

5 ADVERSE REACTIONS

5.1 Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflect exposure to fexofenadine hydrochloride in 5083 patients in trials for allergic rhinitis. In these trials, 3010 patients 12 years of age and older with seasonal allergic rhinitis were exposed to fexofenadine hydrochloride at doses of 20 to 240 mg twice daily or 120 to 180 mg once daily. A total of 646 patients 6 to 11 years of age with seasonal allergic rhinitis were exposed to fexofenadine hydrochloride at doses of 15 to 60 mg twice daily. The duration of treatment in these trials was 2 weeks. A total of 534 patients 6 months to 5 years of age with allergic rhinitis were exposed to fexofenadine hydrochloride at doses of 15 to 30 mg twice daily. The duration of treatment in these trials ranged from 1 day to 2 weeks.

Seasonal Allergic Rhinitis

Adults and Adolescents: In placebo-controlled seasonal allergic rhinitis clinical trials in subjects 12 years of age and older, 2439 subjects received fexofenadine hydrochloride capsules
at doses of 20 mg to 240 mg twice daily. All adverse reactions that were reported by greater than 1% of subjects who received the recommended daily dose of fexofenadine hydrochloride (60 mg capsules twice daily) are listed in Table 1.

In another placebo-controlled clinical study in the United States, 571 subjects aged 12 years and older received fexofenadine hydrochloride tablets at doses of 120 or 180 mg once daily. Table 1 also lists adverse reactions that were reported by greater than 2% of subjects treated with fexofenadine hydrochloride tablets at doses of 180 mg once daily.

The incidence of adverse reactions, including somnolence/fatigue, was not dose-related and was similar across subgroups defined by age, gender, and race.

Table 1
Adverse reactions in subjects aged 12 years and older reported in placebo-controlled seasonal allergic rhinitis clinical trials in the United States

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Fexofenadine 60 mg Twice Daily (n=680) Frequency</th>
<th>Placebo Twice Daily (n=674) Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysmenorrhea</td>
<td>1.5%</td>
<td>0.3%</td>
</tr>
</tbody>
</table>

Once-daily dosing with fexofenadine hydrochloride tablets at rates of greater than 2%

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Fexofenadine 180 mg Once Daily (n=283) Frequency</th>
<th>Placebo (n=293) Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>10.3%</td>
<td>7.2%</td>
</tr>
<tr>
<td>Back Pain</td>
<td>2.5%</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

The frequency and magnitude of laboratory abnormalities were similar in fexofenadine hydrochloride- and placebo-treated subjects.

**Pediatrics:** Table 2 lists adverse reactions in subjects aged 6 years to 11 years of age which were reported by greater than 2% of subjects treated with fexofenadine hydrochloride tablets at a dose of 30 mg twice daily in placebo-controlled seasonal allergic rhinitis studies in the United States and Canada.

Table 2
Adverse reactions reported in placebo-controlled seasonal allergic rhinitis studies in pediatric subjects aged 6 years to 11 years in the United States and Canada at rates of greater than 2%

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Fexofenadine 30 mg Twice Daily (n=209) Frequency</th>
<th>Placebo (n=229) Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cough</td>
<td>3.8%</td>
<td>1.3%</td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>2.9%</td>
<td>0.9%</td>
</tr>
</tbody>
</table>
Table 3 lists adverse reactions in subjects 6 months to 5 years of age which were reported by greater than 2% of subjects treated with fexofenadine hydrochloride in 3 open single- and multiple-dose pharmacokinetic studies and 3 placebo-controlled safety studies with fexofenadine hydrochloride capsule content (484 subjects) and suspension (50 subjects) at doses of 15 mg (108 subjects) and 30 mg (426 subjects) given twice a day.

Table 3
Adverse reactions reported in placebo-controlled studies in pediatric subjects with allergic rhinitis aged 6 months to 5 years of age at rates greater than 2%

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Fexofenadine 15 mg Twice Daily (n=108)</th>
<th>Fexofenadine 30 mg Twice Daily (n=426)</th>
<th>Fexofenadine Total Twice Daily (n=534)</th>
<th>Placebo (n=430)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>12.0%</td>
<td>4.2%</td>
<td>5.8%</td>
<td>8.6%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3.7%</td>
<td>2.8%</td>
<td>3.0%</td>
<td>2.6%</td>
</tr>
<tr>
<td>Somnolence/Fatigue</td>
<td>2.8%</td>
<td>0.9%</td>
<td>1.3%</td>
<td>0.2%</td>
</tr>
<tr>
<td>Rhinorrhea</td>
<td>0.9%</td>
<td>2.1%</td>
<td>1.9%</td>
<td>0.9%</td>
</tr>
</tbody>
</table>

5.2 Postmarketing Experience

In addition to the adverse reactions reported during clinical studies and listed above, the following adverse events have been identified during post-approval use of TELFAST. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Events that have been reported rarely during postmarketing experience include: insomnia, nervousness, sleep disorders or paroniria, and hypersensitivity reactions (including anaphylaxis, urticaria, angioedema, chest tightness, dyspnea, flushing, pruritus, and rash).

6 DRUG INTERACTIONS

6.1 Antacids
Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®) decreased fexofenadine AUC by 41% and $C_{\text{max}}$ by 43%.

6.2 Erythromycin and Ketoconazole
Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism. However, co-administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects. Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In 2 separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n=24, each study). No differences in adverse events or QTc interval were observed when subjects were administered
fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole. The findings of these studies are summarized in the following table:

<table>
<thead>
<tr>
<th>Concomitant Drug</th>
<th>(C_{\text{maxSS}}) (Peak plasma concentration)</th>
<th>(AUC_{\text{ss(0-12h)}}) (Extent of systemic exposure)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythromycin (500 mg every 8 hrs)</td>
<td>+82%</td>
<td>+109%</td>
</tr>
<tr>
<td>Ketoconazole (400 mg once daily)</td>
<td>+135%</td>
<td>+164%</td>
</tr>
</tbody>
</table>

The changes in plasma levels were within the range of plasma levels achieved in adequate and well-controlled clinical trials.

The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models. These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption. This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.

### 7 USE IN SPECIFIC POPULATIONS

#### 7.1 Pregnancy

**Teratogenic Effects:** Pregnancy Category C. There was no evidence of teratogenicity in rats or rabbits at oral doses of terfenadine up to 300 mg/kg (which led to fexofenadine exposures that were approximately 4 and 30 times, respectively, the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs).

In mice, no adverse effects and no teratogenic effects during gestation were observed with fexofenadine hydrochloride at oral doses up to 3730 mg/kg (which led to fexofenadine exposures that were approximately 15 times the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs).

There are no adequate and well controlled studies in pregnant women. Fexofenadine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Nonteratogenic Effects:** Dose-related decreases in pup weight gain and survival were observed in rats exposed to an oral dose of 150 mg/kg of terfenadine (which led to fexofenadine exposures that were approximately 3 times the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs).

#### 7.2 Nursing Mothers

It is not known if fexofenadine is excreted in human milk. There are no adequate and well-controlled studies in women during lactation. Because many drugs are excreted in human
milk, caution should be exercised when fexofenadine hydrochloride is administered to a nursing woman.

7.3 Pediatric Use
The recommended doses of fexofenadine hydrochloride in pediatric patients 3 years to 11 years of age are based on cross-study comparison of the pharmacokinetics of fexofenadine in adults and pediatric subjects and on the safety profile of fexofenadine hydrochloride in both adult and pediatric subjects at doses equal to or higher than the recommended doses. The safety and effectiveness of fexofenadine hydrochloride in pediatric patients under 6 months of age have not been established.

The safety of fexofenadine hydrochloride is based on the administration of TELFAST tablets at a dose of 30 mg twice daily demonstrated in 438 pediatric subjects 6 years to 11 years of age in 2 placebo-controlled 2-week seasonal allergic rhinitis trials. The safety of fexofenadine hydrochloride at doses of 15 mg and 30 mg given once and twice a day has been demonstrated in 969 pediatric subjects (6 months to 5 years of age) with allergic rhinitis in 3 pharmacokinetic studies and 3 safety studies.

The effectiveness of fexofenadine hydrochloride for the treatment of seasonal allergic rhinitis in subjects 6 to 11 years of age was demonstrated in 1 trial (n=411) in which TELFAST tablets 30 mg twice daily significantly reduced total symptom scores compared to placebo, along with extrapolation of demonstrated efficacy in subjects aged 12 years and above, and the pharmacokinetic comparisons in adults and children. The effectiveness of fexofenadine hydrochloride 30 mg twice daily for the treatment of seasonal allergic rhinitis in patients 2 to 5 years of age is based on the pharmacokinetic comparisons in adult and pediatric subjects and an extrapolation of the demonstrated efficacy of fexofenadine hydrochloride in adult subjects with this condition and the likelihood that the disease course, pathophysiology, and the drug’s effect are substantially similar in pediatric patients to those in adult patients. Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.

7.4 Geriatric Use
Clinical studies of TELFAST tablets and capsules did not include sufficient numbers of subjects aged 65 years and over to determine whether this population responds differently from younger subjects. Other reported clinical experience has not identified differences in responses between the geriatric and younger subjects. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology (12.3)].

7.5 Renal Impairment
Based on increases in bioavailability and half-life, a dose of 60 mg once daily is recommended as the starting dose in adult patients with decreased renal function (mild, moderate or severe renal impairment). For pediatric patients with decreased renal function (mild, moderate or severe renal impairment), the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age. [See Dosage and Administration (2.2, 2.3) and Clinical Pharmacology (12.3)].

7.6 Hepatic Impairment
The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.
8 OVERDOSAGE

Dizziness, drowsiness, and dry mouth have been reported with fexofenadine hydrochloride overdose. Single doses of fexofenadine hydrochloride up to 800 mg (6 healthy subjects at this dose level), and doses up to 690 mg twice daily for 1 month (3 healthy subjects at this dose level) or 240 mg once daily for 1 year (234 healthy subjects at this dose level) were administered without the development of clinically significant adverse events as compared to placebo.

In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Following administration of terfenadine, hemodialysis did not effectively remove fexofenadine, the major active metabolite of terfenadine, from blood (up to 1.7% removed).

No deaths occurred at oral doses of fexofenadine hydrochloride up to 5000 mg/kg in mice (110 times the maximum recommended daily oral dose in adults and children based on mg/m²) and up to 5000 mg/kg in rats (230 times the maximum recommended daily oral dose in adults and 210 times the maximum recommended daily oral dose in children based on mg/m²). Additionally, no clinical signs of toxicity or gross pathological findings were observed. In dogs, no evidence of toxicity was observed at oral doses up to 2000 mg/kg (300 times the maximum recommended daily oral dose in adults and 280 times the maximum recommended daily oral dose in children based on mg/m²).

9 DESCRIPTION

Fexofenadine hydrochloride, the active ingredient of TELFAST oral suspension, is a histamine H₁-receptor antagonist with the chemical name (±)-4-[(1 hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid hydrochloride. It has the following chemical structure

![Chemical structure of fexofenadine hydrochloride]

The molecular weight is 538.13 and the empirical formula is C₃₂H₃₉NO₄•HCl.

Fexofenadine hydrochloride is a white to off-white crystalline powder. It is freely soluble in methanol and ethanol, slightly soluble in chloroform and water, and insoluble in hexane. Fexofenadine hydrochloride is a racemate and exists as a zwitterion in aqueous media at physiological pH.

TELFAST oral suspension, a white uniform suspension, contains 6 mg fexofenadine hydrochloride per mL and the following excipients: propylene glycol, edetate disodium, propylparaben, butylparaben, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor (PFC 9950), sucrose, xylitol and purified water.
10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action
Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H₁-receptor antagonist activity. Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects. Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats. The clinical significance of these findings is unknown. In laboratory animals, no anticholinergic or alpha₁-adrenergic blocking effects were observed. Moreover, no sedative or other central nervous system effects were observed. Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.

10.2 Pharmacodynamics
Wheal and Flare: Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by 1 hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours. There was no evidence of tolerance to these effects after 28 days of dosing. The clinical significance of these observations is unknown.

Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 or 60 mg, antihistamine effect was observed at 1 hour and reached a maximum by 3 hours. Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 and 60 mg dose.

No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 to 240 mg twice daily for 2 weeks. Pediatric subjects from 2 placebo-controlled trials (n=855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc. In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for 1 year.

10.3 Pharmacokinetics
The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis

Absorption:
Telast oral suspension: A dose of 5 mL of TELFAST oral suspension containing 30 mg of fexofenadine hydrochloride is bioequivalent to a 30 mg dose of TELFAST tablets. Following oral administration of a 30 mg dose of TELFAST oral suspension to healthy adult subjects, the mean Cmax was 118 ng/mL and occurred at approximately 1 hour. The administration of 30 mg TELFAST oral suspension with a high fat meal decreased the AUC and the mean Cmax by approximately 30 and 47%, respectively in healthy adult subjects.

Distribution:
Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α₁-acid glycoprotein.

Metabolism:
Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.
Elimination:
The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects. Human mass balance studies documented a recovery of approximately 80% and 11% of the $[^{14}C]$ fexofenadine hydrochloride dose in the feces and urine, respectively. Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.

Special Populations:
Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.

Renally Impaired:
In subjects with mild to moderate (creatinine clearance 41-80 mL/min) and severe (creatinine clearance 11-40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects. Peak plasma concentrations in subjects on dialysis (creatinine clearance $\leq$ 10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects. Based on increases in bioavailability and half-life, a dose of 60 mg once daily is recommended as the starting dose in adult patients with decreased renal function. For pediatric patients with decreased renal function, the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age [see Dosage and Administration (2.2, 2.3)].

Hepatically Impaired:
The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.

Geriatric Subjects:
In older subjects ($\geq$ 65 years old), peak plasma levels of fexofenadine were 99% greater than those observed in younger subjects (<65 years old). Mean fexofenadine elimination half-lives were similar to those observed in younger subjects.

Pediatric Subjects:
A population pharmacokinetic analysis was performed with data from 77 pediatric subjects (6 months to 12 years of age) with allergic rhinitis and 136 adult subjects. The individual apparent oral clearance estimates of fexofenadine were on average 44% and 36% lower in pediatric subjects 6 to 12 years (n=14) and 2 to 5 years of age (n=21), respectively, compared to adult subjects.

Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.

Effect of Gender:
Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.
11 NONCLINICAL TOXICOLOGY

11.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

The carcinogenic potential of fexofenadine was assessed using terfenadine studies with adequate fexofenadine exposure (based on plasma area-under-the-concentration vs. time [AUC] values). No evidence of carcinogenicity was observed in an 18-month study in mice and in a 24-month study in rats at oral doses up to 150 mg/kg of terfenadine (which led to fexofenadine exposures that were approximately 3 and 5 times the exposure at the maximum recommended daily oral dose of fexofenadine hydrochloride in adults [180 mg] and children [60 mg] respectively).

In in vitro (Bacterial Reverse Mutation, CHO/HGPRT Forward Mutation, and Rat Lymphocyte Chromosomal Aberration assays) and in vivo (Mouse Bone Marrow Micronucleus assay) tests, fexofenadine hydrochloride revealed no evidence of mutagenicity.

In rat fertility studies, dose-related reductions in implants and increases in postimplantation losses were observed at an oral dose of 150 mg/kg of terfenadine (which led to fexofenadine exposures that were approximately 3 times the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs). In mice, fexofenadine hydrochloride produced no effect on male or female fertility at average oral doses up to 4438 mg/kg (which led to fexofenadine exposures that were approximately 13 times the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs).

11.2 Animal Toxicology and/or Pharmacology

In dogs (30 mg/kg/orally twice daily for 5 days) and rabbits (10 mg/kg, intravenously over 1 hour), fexofenadine hydrochloride did not prolong QTc. In dogs, the plasma fexofenadine concentration was approximately 9 times the therapeutic plasma concentrations in adults receiving the maximum recommended human daily oral dose of 180 mg. In rabbits, the plasma fexofenadine concentration was approximately 20 times the therapeutic plasma concentration in adults receiving the maximum recommended human daily oral dose of 180 mg. No effect was observed on calcium channel current, delayed K+ channel current, or action potential duration in guinea pig myocytes, or on the delayed rectifier K+ channel cloned from human heart at concentrations up to 1 x 10^{-5} M of fexofenadine.

12 CLINICAL STUDIES

12.1 Seasonal Allergic Rhinitis

Adults: In three 2-week, multicenter, randomized, double-blind, placebo-controlled trials in subjects 12 to 68 years of age with seasonal allergic rhinitis (n=1634), fexofenadine hydrochloride 60 mg twice daily significantly reduced total symptom scores (the sum of the individual scores for sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes) compared to placebo. Statistically significant reductions in symptom scores were observed following the first 60 mg dose, with the effect maintained throughout the 12-hour interval. In these studies, there was no additional reduction in total symptom scores with higher doses of fexofenadine hydrochloride up to 240 mg twice daily.

In one 2-week, multicenter, randomized, double-blind clinical trial in subjects 12 to 65 years of age with seasonal allergic rhinitis (n=863), fexofenadine hydrochloride 180 mg once daily significantly reduced total symptom scores (the sum of the individual scores for sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes) compared to placebo. Although the number of subjects in some of the subgroups was small, there were no significant differences in the effect of fexofenadine hydrochloride across subgroups of subjects defined by gender, age, and race. Onset of action for reduction in total symptom scores, excluding nasal congestion, was observed at 60 minutes compared to placebo following a single 60 mg fexofenadine hydrochloride dose administered to subjects with seasonal allergic rhinitis who were exposed to ragweed pollen in an environmental exposure unit. In 1 clinical trial conducted with TELFAST
60 mg capsules, and in 1 clinical trial conducted with TELFAST-D 12 Hour extended release tablets, onset of action was seen within 1 to 3 hours.

**Pediatrics:** Two 2-week, multicenter, randomized, placebo-controlled, double-blind trials in 877 pediatric subjects 6 to 11 years of age with seasonal allergic rhinitis were conducted at doses of 15, 30, and 60 mg (tablets) twice daily. In 1 of these 2 studies, conducted in 411 pediatric subjects, all 3 doses of fexofenadine hydrochloride significantly reduced total symptom scores (the sum of the individual scores for sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes) compared to placebo, however, a dose-response relationship was not seen. The 60 mg twice daily dose did not provide any additional benefit over the 30 mg twice daily dose in pediatric subjects 6 to 11 years of age. Administration of a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults. [See Clinical Pharmacology (12.3)].

13 **HOW SUPPLIED/ STORAGE AND HANDLING**

TELFAST oral suspension (fexofenadine hydrochloride, 30 mg/5 mL (6 mg/mL)) is available in an amber PET bottle containing 150 mL of suspension.

Store TELFAST oral suspension at controlled room temperature not more then 25°C. Shake bottle well, before each use.

Shelf life after first opening the bottle – 30 days.

17. **PATIENT COUNSELING INFORMATION**

Provide the following information to patients and parents/caregivers of pediatric patients taking TELFAST oral suspension:

- TELFAST oral suspension is prescribed for the relief of symptoms of seasonal allergic rhinitis. Instruct patients to take TELFAST only as prescribed. **Do not exceed the recommended dose.** If any untoward effects occur while taking TELFAST, discontinue use and consult a doctor.

- Patients who are hypersensitive to any of the ingredients should not use these products.

- Patients who are pregnant or nursing should use these products only if the potential benefit justifies the potential risk to the fetus or nursing infant.

- Advise patients and parents/caregivers of pediatric patients to store the medication in a tightly closed container in a cool, dry place, away from small children.

Advise patients and parents/caregivers of pediatric patients to shake the TELFAST oral suspension bottle well, before each use.

Manufacturer: sanofi-aventis U.S.
License Holder : sanofi-aventis Israel Ltd.
Fexofenadine HCl 30 mg

This leaflet contains information on the use of Fexofenadine HCl 30 mg tablets, which are indicated for the symptomatic relief of seasonal and non seasonal allergic rhinitis.

**Description:**
Fexofenadine HCl is a non-sedating antihistamine with an extended duration of action.

**Uses:**
Fexofenadine HCl is used to relieve symptoms of allergic rhinitis such as sneezing, runny nose, itchy or watery eyes, and itching of the sides of the nose.

**How to take:**
Take Fexofenadine HCl with food to reduce stomach upset.

**Possible side effects:**
Common side effects include headache, dry mouth, and constipation.

**Contraindications:**
Fexofenadine HCl should not be taken if you are allergic to it or any of its ingredients.

**Precautions:**
Please read the patient information leaflet carefully before using this medicine.

**Missed doses:**
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the usual time.

**Overdose:**
In case of overdose, seek medical attention immediately.

**Interactions:**
Fexofenadine HCl may interact with other medicines, so please inform your doctor or pharmacist before taking any other medicines.

**Storage:**
Store Fexofenadine HCl in a cool, dry place, away from heat and direct sunlight.

**Additional information:**
- Always read the patient information leaflet before taking Fexofenadine HCl.
- If you have any further questions, please consult your doctor or pharmacist.
Telfast Suspension
For oral administration
30 mg/5 ml

How can you contribute to the success of the treatment?

Complete the full course of treatment as instructed by the physician.
Even if there is an improvement in your health, do not discontinue use of this medicine without consulting your physician.

Avoid poisoning:
This medicine, and all other medicines, must be stored in a safe place out of the reach of children and infants, to avoid poisoning. If you have taken an overdose, or if a child has accidentally swallowed the medicine, proceed immediately to a hospital emergency room and bring the package of the medicine with you.
Do not induce vomiting unless explicitly instructed to do so by a physician! This medicine has been prescribed for the treatment of your ailment; in another patient it may cause harm. Do not give this medicine to your relatives, neighbors or acquaintances.
Do not take medicines in the dark! Check the label and the dose each time you take your medicine. Wear your glasses if you need them.

How will this medicine affect your daily life?

Studies have shown that Telfast does not impair alertness; therefore, driving a vehicle while taking the medicine is possible. However, there are care, exceptional cases. Therefore, you should be sure that your child's alertness is not affected by taking the medicine before engaging in activities requiring concentration such as bicycle riding or playing near roads.

Telfast Suspension 30 mg/5 ml

Composition:

Each 5 ml contains 1000 mg sucrose.

In active conditions:
- Antihistamine.

Therapeutic activity:
- For relief in cases of seasonal allergic rhinitis in children from 3 to 11 years of age.

When should the preparation not be used?

Do not use this medicine if there is a known sensitivity to any of its ingredients.

Do not take this medicine without consulting a physician before starting treatment.
If you are suffering, or have suffered in the past, from impaired kidney function. This medicine is intended for use in children. However attention should be paid to the issue of the medicine's safety during pregnancy and breastfeeding - do not use the medicine without consulting the physician before commencing treatment.

If you are pregnant, planning to become pregnant, or breastfeeding.

If you forget to take this medicine at the specified time, take the dose as soon as you remember, but never take two doses together.

If you accidentally took a double dose, refer to the attending physician.

Attention:
Allow a lapse of at least two hours between taking this medicine and taking antacids that contain aluminium and/or magnesium. Make sure to measure the dose with the attached measuring spoon.

Directions for use:
For oral use. Shake well before using.

Composition:
Each 5 ml contains:
- Fexofenadine HCl 30 mg
- Water Purified, Sucrose, Xylitol, Propylene Glycol, Sodium Phosphate Dibasic Heptahydrate, Sodium Phosphate Monobasic Monohydrate, Artificial Raspberry Cream Flavor (P9 1950), Xanthan Gum, Edetate Disodium, Titanium Dioxide, Poloxamer 407, Propylparaben, Butylparaben

Each 5 ml contains 1000 mg sucrose.

In active conditions:
- Antihistamine.

Therapeutic activity:
- For relief in cases of seasonal allergic rhinitis in children from 3 to 11 years of age.

When should the preparation not be used?

Do not use this medicine if there is a known sensitivity to any of its ingredients.

Do not take this medicine without consulting a physician before starting treatment.
If you are suffering, or have suffered in the past, from impaired kidney function. This medicine is intended for use in children. However attention should be paid to the issue of the medicine's safety during pregnancy and breastfeeding - do not use the medicine without consulting the physician before commencing treatment.

If you are pregnant, planning to become pregnant, or breastfeeding.

If you forget to take this medicine at the specified time, take the dose as soon as you remember, but never take two doses together.

If you accidentally took a double dose, refer to the attending physician.

Attention:
Allow a lapse of at least two hours between taking this medicine and taking antacids that contain aluminium and/or magnesium. Make sure to measure the dose with the attached measuring spoon.

Directions for use:
For oral use. Shake well before using.

This medicine, and all other medicines, must be stored in a safe place out of the reach of children and infants, to avoid poisoning. If you have taken an overdose, or if a child has accidentally swallowed the medicine, proceed immediately to a hospital emergency room and bring the package of the medicine with you.
Do not induce vomiting unless explicitly instructed to do so by a physician! This medicine has been prescribed for the treatment of your ailment; in another patient it may cause harm. Do not give this medicine to your relatives, neighbors or acquaintances.
Do not take medicines in the dark! Check the label and the dose each time you take your medicine. Wear your glasses if you need them.

Storage:
Below 25°C. Do not use beyond 30 days after the bottle is first opened.

Recommended dosage unless otherwise prescribed by your physician:
Children from 3 to 11 years of age: 30 mg (5 ml) once a day (starting dosage) in cases of reduced kidney function.
Do not exceed the recommended dosage.
This medicine is not usually intended for children under 3 years of age.

Do not use beyond 30 days after the bottle is first opened.

If you are suffering, or have suffered in the past, from impaired kidney function. This medicine is intended for use in children. However attention should be paid to the issue of the medicine's safety during pregnancy and breastfeeding - do not use the medicine without consulting the physician before commencing treatment.

If you are pregnant, planning to become pregnant, or breastfeeding.

If you forget to take this medicine at the specified time, take the dose as soon as you remember, but never take two doses together.

If you accidentally took a double dose, refer to the attending physician.

Attention:
Allow a lapse of at least two hours between taking this medicine and taking antacids that contain aluminium and/or magnesium. Make sure to measure the dose with the attached measuring spoon.

Directions for use:
For oral use. Shake well before using.

Composition:
Each 5 ml contains: Fexofenadine HCl 30 mg, Water Purified, Sucrose, Xylitol, Propylene Glycol, Sodium Phosphate Dibasic Heptahydrate, Sodium Phosphate Monobasic Monohydrate, Artificial Raspberry Cream Flavor (P9 1950), Xanthan Gum, Edetate Disodium, Titanium Dioxide, Poloxamer 407, Propylparaben, Butylparaben

Each 5 ml contains 1000 mg sucrose.

In active conditions:
- Antihistamine.

Therapeutic activity:
- For relief in cases of seasonal allergic rhinitis in children from 3 to 11 years of age.

When should the preparation not be used?

Do not use this medicine if there is a known sensitivity to any of its ingredients.

Do not take this medicine without consulting a physician before starting treatment.
If you are suffering, or have suffered in the past, from impaired kidney function. This medicine is intended for use in children. However attention should be paid to the issue of the medicine's safety during pregnancy and breastfeeding - do not use the medicine without consulting the physician before commencing treatment.

If you are pregnant, planning to become pregnant, or breastfeeding.

If you forget to take this medicine at the specified time, take the dose as soon as you remember, but never take two doses together.

If you accidentally took a double dose, refer to the attending physician.

Attention:
Allow a lapse of at least two hours between taking this medicine and taking antacids that contain aluminium and/or magnesium. Make sure to measure the dose with the attached measuring spoon.

Directions for use:
For oral use. Shake well before using.

This medicine, and all other medicines, must be stored in a safe place out of the reach of children and infants, to avoid poisoning. If you have taken an overdose, or if a child has accidentally swallowed the medicine, proceed immediately to a hospital emergency room and bring the package of the medicine with you.
Do not induce vomiting unless explicitly instructed to do so by a physician! This medicine has been prescribed for the treatment of your ailment; in another patient it may cause harm. Do not give this medicine to your relatives, neighbors or acquaintances.
Do not take medicines in the dark! Check the label and the dose each time you take your medicine. Wear your glasses if you need them.

Storage:
Below 25°C. Do not use beyond 30 days after the bottle is first opened.

If you are suffering, or have suffered in the past, from impaired kidney function. This medicine is intended for use in children. However attention should be paid to the issue of the medicine's safety during pregnancy and breastfeeding - do not use the medicine without consulting the physician before commencing treatment.

If you are pregnant, planning to become pregnant, or breastfeeding.

If you forget to take this medicine at the specified time, take the dose as soon as you remember, but never take two doses together.

If you accidentally took a double dose, refer to the attending physician.

Attention:
Allow a lapse of at least two hours between taking this medicine and taking antacids that contain aluminium and/or magnesium. Make sure to measure the dose with the attached measuring spoon.

Directions for use:
For oral use. Shake well before using.